Syrebo recently strengthened its presence in Egypt through participation in the ECU-CRACM Joint International Pharmacy Conference, an international academic event that brought together healthcare professionals, researchers, and industry innovators. The conference and its related activities received attention from official and mainstream media, including communications shared by the Chinese Embassy in Egypt, coverage by Xinhua News Agency, and reports from local Egyptian media. Visual materials from the event included Syrebo's การฟื้นฟูสมรรถภาพ technologies, reflecting the company's active involvement in international academic and professional exchange.

During the conference, Syrebo presented two of its flagship การฟื้นฟูสมรรถภาพ solutions: the Hand หุ่นยนต์ฟื้นฟูสมรรถภาพ for Clinics and the Low & Medium Frequency การรักษาด้วยไฟฟ้า System. These technologies drew interest from การฟื้นฟูสมรรถภาพ specialists, hospital representatives, and industry partners, highlighting the growing demand for intelligent and clinically oriented การฟื้นฟูสมรรถภาพ solutions in the region.

Syrebo's participation formed part of a broader market visit aimed at strengthening collaboration with local partners and gaining deeper insight into Egypt's การฟื้นฟูสมรรถภาพ and healthcare landscape. The event provided a valuable platform for exchanging clinical perspectives and exploring future opportunities for technology application and training.
As part of the visit, Syrebo CEO Gavin Yin attended the International Scientific Day, where he met with Syrebo's Egyptian partners to discuss cooperation plans for the coming year. The meeting reinforced mutual trust and laid the foundation for continued collaboration in clinical support, professional training, and the introduction of advanced การฟื้นฟูสมรรถภาพ technologies to local healthcare institutions.

Syrebo remains committed to working closely with global medical communities and industry partners, promoting innovative การฟื้นฟูสมรรถภาพ solutions that support both clinicians and patients worldwide.